CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Clinics, ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Josephs joins forces with LifeRx.md to redefine health through doctor-led GLP‑1 wellness programs—merging celeb credibility ...

Discover a recent report that states that, although GLP-1 medicines are generally well tolerated, there have been cases of ...

There are two ways in which industry can respond to the GLP-1 craze. On the one hand, they can, like Nestlé, create smaller ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...